Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Biliary Tract Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07670273
What this trial is testing

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

Who this might be right for
Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital 70
Post-approval studies (Phase 4)Not Yet RecruitingNCT07768358
What this trial is testing

Tucatinib Continuation Study

Who this might be right for
HER2-positive Breast CancerCervical CancerBiliary Tract Neoplasms+4 more
Pfizer 175
Testing effectiveness (Phase 2)UnknownNCT03185988
What this trial is testing

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Who this might be right for
Targeted TherapyHER2Biliary Tract Cancer+2 more
Shen Lin 100
Testing effectiveness (Phase 2)Looking for participantsNCT06778031
What this trial is testing

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Who this might be right for
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 54
Not applicableLooking for participantsNCT07124000
What this trial is testing

DESTINY-PANTUMOUR04

Who this might be right for
Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more
AstraZeneca 100
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Testing effectiveness (Phase 2)Ended earlyNCT00478140
What this trial is testing

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Who this might be right for
Adenocarcinoma of the Extrahepatic Bile DuctAdenocarcinoma of the GallbladderMalignant Neoplasm+4 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Looking for participantsNCT05523947
What this trial is testing

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Who this might be right for
HER2-Positive Solid Tumor
Yuhan Corporation 147
Testing effectiveness (Phase 2)Looking for participantsNCT06431490
What this trial is testing

TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 102
Early research (Phase 1)UnknownNCT02662348
What this trial is testing

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+3 more
Yi Miao 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04430738
What this trial is testing

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Who this might be right for
Colorectal CarcinomaGastric AdenocarcinomaGEJ Adenocarcinoma+3 more
Seagen, a wholly owned subsidiary of Pfizer 40
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07159217
What this trial is testing

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract CancerDisitamab VedotinLenvatinib+1 more
Peking Union Medical College Hospital 65
Testing effectiveness (Phase 2)Looking for participantsNCT05969860
What this trial is testing

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Who this might be right for
Advanced Anal CarcinomaAdvanced Biliary Tract CarcinomaAdvanced Bladder Carcinoma+41 more
Mayo Clinic 220